NCT06842355View on ClinicalTrials.gov

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

June 30, 2030

Conditions
Achondroplasia
Interventions
DRUG

TYRA-300 0.125 mg/kg

Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.25 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.375 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.50 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

Trial Locations (4)

3052

RECRUITING

Royal Children's Hospital, Parkville

19803

RECRUITING

Nemours Alfred I duPont Hospital for Children, Wilmington

63130

RECRUITING

Washington University, St Louis

80045

RECRUITING

Children's Hospital Colorado, Aurora

All Listed Sponsors
lead

Tyra Biosciences, Inc

INDUSTRY